Appearance
The Mapping War
CARTO's 50%+ share was built on two decades of workflow dominance and a locked ecosystem. The ecosystem got unlocked by a court. Medtronic built a catheter that doesn't need a mapping system at all. And CMS just opened ASCs to cardiac ablation.
CARTO vs Affera
Affera doesn't compete on features. It competes by making CARTO irrelevant for simple AF.
| CARTO 3 | Affera (Sphere-9) | |
|---|---|---|
| Capital cost | ~$500K | $0 (disposable) |
| FDA adverse events | 87 | 401 |
| Deaths | 2 | 5 |
| Design flaws | 4 | 32 |
| Electrical failures | 0 | 63 |
So what: CARTO has 4 design flaws in two years. Affera has 32 design flaws, 63 electrical failures, and 7 software bugs in year one. But hospitals choose Affera because it eliminates a $500K capital decision — and Medtronic's ablation revenue grew 71% YoY on this strategy.
- CARTO holds: Complex cases, training, multi-catheter workflows, academic centers.
- CARTO loses: Community hospitals doing simple AF. ASCs. New programs avoiding capital.
CARTO vs BSX Mapping
Opal HDx (rebranded RHYTHMIA) now shows 650 FDA adverse events — but zero deaths and only 5 design flaws, mostly usability reports as BSC scales the platform.
The real threat: BSC is building toward a complete PFA + mapping ecosystem:
- FARAWAVE NAV: Integrated navigation with Opal HDx. Already in market.
- Farapoint: FDA approved Jan 2026. First focal PFA catheter. Point-by-point ablation capability BSC previously lacked.
- Faraflex: Single catheter that maps and ablates. First-in-human Feb 2025 (ELEVATE-PF study). 8 Fr (vs 12 Fr Farawave). When this launches, BSC will have market-leading PFA and integrated mapping — directly targeting Affera's model and CARTO's workflow.
The Antitrust Reframe
The $442M judgment ended CARTO's locked ecosystem. Competitors will reference it.
The response: CARTO is now the most open and most proven platform. Compatible with reprocessed catheters ($400-800/case savings). 20 years of evidence. Open by court order — and better for it.
PFA Class-Wide Risks
Every PFA platform has these problems. J&J should surface them — J&J is the only company that also sells RF.
Hemolysis: Universal, Manageable
A 2026 meta-analysis quantified the class-wide signal:
- PFA hemolysis incidence: 9.0% vs 0% for RF ablation
- Lab markers: LDH +63.79 U/L, haptoglobin -0.30 g/L, bilirubin +1.91 umol/L
- AKI incidence: 0% to 5.26% across studies, depending on comorbidities and hydration
- Mitigation: IV fluid loading (0.9% NaCl, 2L+) effectively prevents creatinine elevation. Now standard of care.
Device-specific note: Abbott Volt reported zero clinically relevant hemolysis in the VOLT-AF IDE (392 patients). PulseSelect may produce less hemolysis than FARAPULSE while maintaining equivalent lesion quality. If these findings hold in broader use, hemolysis may become a competitive differentiator, not just a class-wide issue.
The J&J advantage: "When hemolysis risk is elevated, we switch to QDOT MICRO. Can your competitor?"
Coronary Narrowing: Transient, Not Progressive
Updated with longitudinal follow-up data:
- Acute: Wall area +17%, luminal area -10% at 3 months (OCT imaging)
- Long-term (16-month median): No angina, no ACS, no revascularization. No new luminal irregularities.
- Conclusion: Appears to be a transient/stable remodeling phenomenon, not progressive narrowing.
So what: "PFA is excellent for standard PVI. For lesions near coronary arteries, RF remains safer. We offer both."
Stroke: Technique-Dependent, Not Platform-Inherent
The HRS/EHRA issued a joint scientific statement on PFA (Feb 12, 2026), addressing the emerging safety landscape:
- MANIFEST-US: Stroke rate ~0.1% (1 in 1,000) across 41,968 patients
- VARIPULSE post-correction: 0.22% in 6,811 patients
- Omnypulse pilot: Zero MRI-detected cerebral lesions (n=30)
Stroke risk correlates with ablation technique (stacking, ablation outside PVs) rather than platform selection. The HRS/EHRA statement provides a credible framework for addressing safety questions.
The ASC Decision
CMS added cardiac catheter ablation (CPT 93656) to ASC-covered procedures effective January 1, 2026 at $20,512 per PVI. This is the biggest structural change in EP access in two decades.
What Changed
| Before Jan 1, 2026 | After Jan 1, 2026 |
|---|---|
| AF ablation: hospital inpatient/outpatient only | AF ablation: ASCs eligible |
| VARIPULSE requires CARTO ($500K) | Same requirement; ASCs won't pay it |
| Abbott Volt doesn't exist | Volt: conscious sedation + no capital = ASC-native |
| Affera requires $0 capital | Same advantage, now in a setting that rewards it |
VARIPULSE's ASC Position
VARIPULSE has one ASC advantage and one ASC problem:
- Advantage: 87.9% same-day discharge rate (VARISURE, 850 procedures) — higher than reported rates for other PFA platforms
- Problem: Requires CARTO ($500K capital). No ASC will make that purchase.
| Option | What It Means | Risk |
|---|---|---|
| Standalone VARIPULSE | Simplified PVI without full mapping | Engineering investment; may cannibalize CARTO |
| CARTO-lite for ASCs | Lower capital cost ($150-200K) | Margin compression |
| Concede ASCs | Focus CARTO on hospital labs | Cedes 30-40% of PFA growth |
Abbott's Volt (conscious sedation, no general anesthesia) is an ASC-native advantage. Affera's $0 capital cost eliminates the purchasing committee entirely.
The worst outcome is no decision. Every quarter without an ASC strategy is a quarter competitors build installed base you'll never win back. CMS just made this urgent.
Hemolysis meta-analysis (Heart Rhythm Journal, 2026). Coronary imaging: JACC Clinical EP (2025, longitudinal OCT). HRS/EHRA PFA Scientific Statement (Feb 2026). CMS 2026 OPPS Final Rule. VARISURE Safety Survey (850 procedures, 2026 AF Symposium).